103855-01-2Relevant articles and documents
From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis
Devine, William G.,Diaz-Gonzalez, Rosario,Ceballos-Perez, Gloria,Rojas, Domingo,Satoh, Takashi,Tear, Westley,Ranade, Ranae M.,Barros-álvarez, Ximena,Hol, Wim G. J.,Buckner, Frederick S.,Navarro, Miguel,Pollastri, Michael P.
, p. 225 - 236 (2017)
Human African trypanosomiasis is a neglected tropical disease that is lethal if left untreated. Existing therapeutics have limited efficacy and severe associated toxicities. 2-(2-(((3-((1H-Benzo[d]imidazol-2-yl)amino)propyl)amino)methyl)-4,6-dichloro-1H-indol-1-yl)ethan-1-ol (NEU-1053) has recently been identified from a high-throughput screen of >42,000 compounds as a highly potent and fast-acting trypanocidal agent capable of curing a bloodstream infection of Trypanosoma brucei in mice. We have designed a library of analogues to probe the structure-activity relationship and improve the predicted central nervous system (CNS) exposure of NEU-1053. We report the activity of these inhibitors of T. brucei, the efficacy of NEU-1053 in a murine CNS model of infection, and identification of the target of NEU-1053 via X-ray crystallography.
Remarkable Enhancement in Boron Uptake Within Glioblastoma Cells With Carboranyl–Indole Carboxamides
Narlawar, Rajeshwar,Austin, Christopher J. D.,Kahlert, Jan,Selleri, Silvia,Da Pozzo, Eleonora,Martini, Claudia,Werry, Eryn L.,Rendina, Louis M.,Kassiou, Michael
, p. 3321 - 3327 (2018)
Novel boron-rich, carboranyl–indole carboxamide ligands were prepared and found to effectively target the 18 kDa translocator protein (TSPO), an upregulated mitochondrial membrane-bound protein which has been observed in variety of tumor cell lines and its expression appears to be proportional to the degree of tumorigenicity, emphasizing a key role in cancer cell proliferation. Both boronated compounds displayed remarkably high affinities for the TSPO. In addition, the in vitro uptake of these compounds into T98G human glioma cells was found to be 25- to 100-fold greater than that of clinical boron neutron capture therapy (BNCT) agents.
INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF
-
, (2014/03/26)
A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein.
A simple and efficient synthesis of ethyl 1-Aryl-4-formyl-1H-pyrazole-3- carboxylates
Matiychuk, Vasyl S.,Potopnyk, Mykhaylo A.,Obushak, Mykola D.
, p. E43-E47 (2013/06/04)
A new simple and convenient method of synthesis of ethyl 1-aryl-4-formyl-1H-pyrazole-3-carboxylates from aromatic amines via diazonium salts has been developed. Hydrolysis and hydrazinolyization of these compounds has been investigated.
SUBSTITUTED INDOLE COMPOUND
-
Page/Page column 182-183, (2010/11/24)
Disclosed is an excellent LXR modulator. A compound represented by the general formula (I): (I) wherein R1, R2, R3 and R4: H, an alkyl which may be substituted, OH, an alkoxy which may be substituted, an amino which may be substituted, a halogeno, a phenyl or the like; R5: H or an alkyl; R6: -COR8 (wherein R8: an alkoxy which may be substituted, a phenyloxy which may be substituted, an amino which may be substituted, or the like), -SO2R9 (wherein R9: an alkyl which may be substituted, a phenyl which may be substituted or a heterocyclyl which may be substituted), or an alkyl which may be substituted; R7: -X2R10 [wherein R10: -COR11 (where R11: OH, an alkoxy which may be substituted or an amino which may be substituted), -SO2R12 (where R12: an alkyl which may be substituted or amino which may be substituted), -N(R13)COR14 (where R13: H or an alkyl which may be substituted; R14: H or an alkyl which may be substituted), -N(R13)SO2R15 (where R13: as defined above; R15: an alkyl which may be substituted) or tetrazol-5-yl; and X2: a single bond or an alkylene which may be substituted]; X1: a methylene which may be substituted; Y1: a phenyl which may be substituted or a heterocyclyl which may be substituted; and Y2: an aryl which may be substituted, a heterocyclyl which may be substituted or the like], or the like.
NMDA (N-METHYL-D-ASPARTATE) ANTAGONISTS
-
Page/Page column 15, (2010/02/14)
The present invention is new excitatory amino acid antagonists (herein referred to as compounds of formula (1)). These new antagonists are useful as NMDA (N-methyl-D-aspartate) antagonists.
Chemical development of MDL 103371: An N-methyl-D-aspartate-type glycine receptor antagonist for the treatment of stroke
Watson, Timothy J.N.,Horgan, Stephen W.,Shah, Ramnik S.,Farr, Robert A.,Schnettler, Richard A.,Nevill Jr., C. Richard,Weiberth, Franz J.,Huber, Edward W.,Baron, Bruce M.,Webster, Mark E.,Mishra, Rajesh K.,Harrison, Boyd L.,Nyce, Phillip L.,Rand, Cynthia L.,Goralski, Christian T.
, p. 477 - 487 (2013/08/07)
MDL 103371 is a N-methyl-D-aspartate (NMDA)-type glycine receptor antagonist for the potential treatment of stroke. Evaluation of five different synthetic routes, which included Stille, Suzuki, enol ether, Knoevenagel, and the Mukaiyama coupling reactions
3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
-
, (2008/06/13)
The present invention is new 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof. These new 3-indolyl-3-yl-prpopenoic acid derivatives are useful as NMDA antagonist.
